Izenburua
Deep Learning-based age prediction models from retinal Optical Coherence Tomography imagesBeste erakundeak
https://ror.org/00wvqgd19Instituto de Investigación Sanitaria Biobizkaia
Ikerbasque
Bertsioa
PostprintaDokumentu-mota
Kongresu-ekarpenaBahituraren amaiera data
2145-12-31Hizkuntza
IngelesaEskubideak
© 2025 CASEIBSarbidea
Sarbide bahituaIdentifikadorea
https://caseib.es/2025/wp-content/uploads/2025/12/CASEIB2025_LibrodeActas.zipNon argitaratua
Congreso Anual de la Sociedad Española de Ingeniería Biomédica (CASEIB) 43. Zaragoza, 19-21 noviembre, 2025Argitaratzailea
Sociedad Española de Ingeniería BiomédicaGaia (UNESCO Tesauroa)
Komunikazioaren teknologiaLaburpena
This study evaluates the potential of Optical Coherence Tomog
raphy (OCT) as a non-invasive tool for retinal age prediction in
healthy individuals. A dataset comprising 1,180 eyes from 517 con
trol ... [+]
This study evaluates the potential of Optical Coherence Tomog
raphy (OCT) as a non-invasive tool for retinal age prediction in
healthy individuals. A dataset comprising 1,180 eyes from 517 con
trol subjects was used to compare deep learning models trained on
different OCT scan types: peripapillary B-scans, individual macula
raster B-Scans, and full macular volumes. Images underwent stan
dardized preprocessing, and models based on 2D and 3D ResNet
architectures were trained and optimized using Transfer Learning.
Results show that volumetric macular scans applied in a ResNet
3D model achieved the lowest Mean Absolute Error (3.07 years),
outperforming both previous literature and all tested 2D configura
tions. Overall, findings highlight that integrating depth and spatial
features in OCT data significantly enhances retinal age estimation. [-]
Finantzatzailea
Gobierno VascoGobierno Vasco
Programa
Ikertalde Convocatoria 2022-2023Proyectos de investigación y desarrollo en salud 2024
Zenbakia
IT1451-222024333045
Laguntzaren URIa
Sin informaciónSin información
Proiektua
Teoría de la Señal y Comunicaciones (IKERTALDE 2022-2023)Creación de apósitos con plasma rico en plaquetas alogénicos para la curación de heridas crónicas (ALOPRP3D IV)


















